Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), is a newly emerging infectious virus which was first identified in Saudi Arabia in June 2012 (Zaki et al., 2012). Since 2012, MERS-CoV has infected 2,229 humans, including 791 deaths (mortality rate ~35%), in at least 27 countries, including Saudi Arabia, South Korea, Iran, Jordan, Qatar, United Kingdom, United States, China, and Thailand. The virus likely uses bats as its natural host, but and replicates in them without showing clinical signs of disease. Dromedary camels are an intermediate host of MERS-CoV and MES-CoV is able to transmit from camels to camels, which demonstrate high seropositivity to MERS-CoV. Transmission of virus from camels to humans has occurred, by direct contact with MERS-CoV-infected dromedary camels by camel workers (reviewed in Zhou et al., 2018).
MERS-CoV has been added to the WHO Blueprint list of priority viruses that cause public health emergency but still lack efficacious drugs and vaccines (WHO, 2018). The majority of MERS vaccines under development are based on MERS-CoV Spike protein, including full-length S, S1, and receptor-binding domain (RBD) (reviewed in Zhou et al. 2018).
Recombinant protein corresponding to Coronavirus (MERS-CoV S1), fused to Fc-Tag, expressed in Mammalian Cell.
Applications:Suitable for use in ELISA. Other applications not tested.
Recommended Dilution:Optimal dilutions to be determined by the researcher.
Storage and Stability:May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 6 months after receipt at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
仕様
Size：100ug
Source Antigen：Recombinant, Mammalian Cell
Grade：Purified
Purity：≥85%
Form：Supplied as a liquid in PBS, pH 7.4. No preservative added.
